257 related articles for article (PubMed ID: 8918625)
1. Safety of intravenous injection of iron saccharate in haemodialysis patients.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1996 Sep; 11(9):1797-802. PubMed ID: 8918625
[TBL] [Abstract][Full Text] [Related]
2. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration.
Parkkinen J; von Bonsdorff L; Peltonen S; Grönhagen-Riska C; Rosenlöf K
Nephrol Dial Transplant; 2000 Nov; 15(11):1827-34. PubMed ID: 11071973
[TBL] [Abstract][Full Text] [Related]
3. Importance of iron supply for erythropoietin therapy.
Sunder-Plassmann G; Hörl WH
Nephrol Dial Transplant; 1995 Nov; 10(11):2070-6. PubMed ID: 8643170
[TBL] [Abstract][Full Text] [Related]
4. Effect of repeated intravenous iron administration in haemodialysis patients on serum 8-hydroxy-2'-deoxyguanosine levels.
Maruyama Y; Nakayama M; Yoshimura K; Nakano H; Yamamoto H; Yokoyama K; Lindholm B
Nephrol Dial Transplant; 2007 May; 22(5):1407-12. PubMed ID: 17264097
[TBL] [Abstract][Full Text] [Related]
5. Intravenous iron sucrose in Chinese hemodialysis patients with renal anemia.
Li H; Wang SX
Blood Purif; 2008; 26(2):151-6. PubMed ID: 18212498
[TBL] [Abstract][Full Text] [Related]
6. 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit(R)) in haemodialysis patients.
Zanen AL; Adriaansen HJ; van Bommel EF; Posthuma R; Th de Jong GM
Nephrol Dial Transplant; 1996 May; 11(5):820-4. PubMed ID: 8671901
[TBL] [Abstract][Full Text] [Related]
7. The effect of i.v. iron alone or in combination with low-dose erythropoietin in the rapid correction of anemia of chronic renal failure in the predialysis period.
Silverberg DS; Blum M; Agbaria Z; Deutsch V; Irony M; Schwartz D; Baruch R; Yachnin T; Steinbruch S; Iaina A
Clin Nephrol; 2001 Mar; 55(3):212-9. PubMed ID: 11316241
[TBL] [Abstract][Full Text] [Related]
8. Intravenous iron supplementation in children on hemodialysis.
Leijn E; Monnens LA; Cornelissen EA
J Nephrol; 2004; 17(3):423-6. PubMed ID: 15365964
[TBL] [Abstract][Full Text] [Related]
9. The efficiency of fractionated parenteral iron treatment in CAPD patients.
Akcicek F; Ozkahya M; Cirit M; Ok E; Unsal A; Toz H; Celik A; Atabay G; Basci A
Adv Perit Dial; 1997; 13():109-12. PubMed ID: 9360661
[TBL] [Abstract][Full Text] [Related]
10. Low-dose continuous iron therapy leads to a positive iron balance and decreased serum transferrin levels in chronic haemodialysis patients.
Canavese C; Bergamo D; Ciccone G; Burdese M; Maddalena E; Barbieri S; Thea A; Fop F
Nephrol Dial Transplant; 2004 Jun; 19(6):1564-70. PubMed ID: 15004263
[TBL] [Abstract][Full Text] [Related]
11. Intravenous iron attenuates postvaccination anti-HBsAg titres after quadruple hepatitis B vaccination in dialysis patients with erythropoietin therapy.
Liu JH; Liu YL; Lin HH; Yang YF; Kuo HL; Lin PW; Huang CC
Int J Clin Pract; 2009 Mar; 63(3):387-93. PubMed ID: 18410348
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
13. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
Chen YC; Hung SC; Tarng DC
Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
[TBL] [Abstract][Full Text] [Related]
14. Monitoring iron status in end-stage renal disease patients on hemodialysis.
Rafi A; Karkar A; Abdelrahman M
Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
[TBL] [Abstract][Full Text] [Related]
15. Serum hepcidin concentration in chronic haemodialysis patients: associations and effects of dialysis, iron and erythropoietin therapy.
Weiss G; Theurl I; Eder S; Koppelstaetter C; Kurz K; Sonnweber T; Kobold U; Mayer G
Eur J Clin Invest; 2009 Oct; 39(10):883-90. PubMed ID: 19563467
[TBL] [Abstract][Full Text] [Related]
16. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion.
Kooistra MP; Kersting S; Gosriwatana I; Lu S; Nijhoff-Schutte J; Hider RC; Marx JJ
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():36-41. PubMed ID: 11886430
[TBL] [Abstract][Full Text] [Related]
17. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.
Schiesser D; Binet I; Tsinalis D; Dickenmann M; Keusch G; Schmidli M; Ambühl PM; Lüthi L; Wüthrich RP
Nephrol Dial Transplant; 2006 Oct; 21(10):2841-5. PubMed ID: 16891647
[TBL] [Abstract][Full Text] [Related]
18. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
19. Use of bolus intraperitoneal iron dextran in continuous ambulatory peritoneal dialysis or continuous cyclic peritoneal dialysis patients receiving recombinant human erythropoietin.
Mars RL; Moles K; Pope K; Hargrove P
Adv Perit Dial; 1999; 15():60-4. PubMed ID: 10682073
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of bolus intravenous iron dextran treatment in peritoneal dialysis patients receiving recombinant human erythropoietin.
Ahsan N; Groff JA; Waybill MA
Adv Perit Dial; 1996; 12():161-6. PubMed ID: 8865893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
